Brief: CEL-SCI Gets FDA Go-Ahead For Study Of Multikine In Treatment Of Head, Neck Cancer
08/05/2024 14:18
May 8 (Reuters) - CEL-SCI Corp CVM.A :
* CEL-SCI RECEIVES FDA GO-AHEAD FOR ITS CONFIRMATORY STUDY
OF
MULTIKINE IN THE TREATMENT OF HEAD & NECK CANCER
Source text for Eikon: ID:nBw9HRlyba
Further company coverage: CVM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CEL-SCI
See all newsBrief: CEL-SCI Announces Closing Of Offering
Brief: Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing
Brief: Cel-Sci Corporation Announces Pricing Of Public Offering
Brief: CEL-SCI Enters Strategic Agreement With Amarox For The Registration, Commercialization, And Distribution Of Multikine In Saudi Arabia
Drug developer CEL-SCI dives on deep-discounted equity raise